AN2 Therapeutics, Inc. 8-K

What Happened

• On May 11, 2026 AN2 Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026 via a press release. The full text of that press release is attached to the Form 8-K as Exhibit 99.1 and is incorporated by reference in the filing under Item 2.02.

Key Details

• Filing date: May 11, 2026. Quarter covered: Q1 2026 (ended March 31, 2026).
• Disclosure type: Item 2.02 — Results of Operations and Financial Condition (press release furnished).
• Exhibit: Press release is attached as Exhibit 99.1. Per Item 9.01, the exhibit is furnished (not “filed”) and is not to be deemed incorporated by reference into other SEC filings except as expressly stated.
• The 8-K does not report other event types (e.g., executive changes or mergers) beyond the Q1 results disclosure.

Why It Matters

• This filing provides AN2’s latest quarterly results and related commentary that can affect investor views on the company’s earnings, revenue, cash position and near-term prospects. Retail investors should read the attached press release (Exhibit 99.1) for the specific financial figures, operational highlights and any management commentary, since the 8-K itself furnishes those results rather than filing them as an incorporated exhibit.